Rania Baleela: Evaluating Bedside Diagnostics and VICC Outcomes in Hemotoxic Snakebite
Rania Baleela, Associate Professor of Molecular Biology at Faculty of Science, University of Khartoum, shared a post on LinkedIn:
“I am pleased to share our newly published open-access study in Tropical Medicine and Health.
‘Outcomes of venom-induced consumption coagulopathy following snakebite envenoming in Sudan: a cohort study.”
Snakebite envenoming remains an important but under-recognised public health problem in Sudan.
In this hospital-based cohort of 119 snakebite patients, we found that 80.7% developed venom-induced consumption coagulopathy (VICC).
Among patients with VICC:
- 88.5% experienced spontaneous bleeding
- 30.2% developed severe haemorrhage, most commonly intracerebral bleeding
- 29.4% of all patients developed acute kidney injury
- 30.2% of patients with VICC died in hospital
- The 20-minute whole blood clotting test (WBCT20) showed 100% sensitivity for VICC in this cohort, supporting its value as an accessible bedside screening tool, while laboratory confirmation remains important.
These findings highlight the substantial clinical burden of haemotoxic snakebite in Sudan and the urgent need to strengthen snakebite surveillance, access to appropriate antivenom, diagnostic capacity, and evidence-based clinical management.
I am grateful to all co-authors, the patients and their families, and the clinical team at Sinja Teaching Hospital for their contributions to this work.
Read the full open-access article on Springer Nature.”
Title: Outcomes of venom-induced consumption coagulopathy following snakebite envenoming in Sudan: a cohort study
Authors: Abdallateif A. Omer, Abdelsalam M. A. Nail, Burhan A. Mohammed, Rayan Ali Tonga, Tarig Elsammani Eisa, Fatima Altahir, Rania M. H. Baleela, GadAllah Modawe
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 13, 2026, 11:15Bridging Neurology and Thrombosis: Key Priorities from a New Expert Consensus Report – International Journal of Stroke
-
Aug 13, 2026, 11:05Khaled Musallam: The Evolving Landscape of β-Thalassemia: Clinical Trial Advances Since 2021
-
Aug 13, 2026, 10:31Brad Wilson: Clinical Insights from the Landmark ESC 2026 Trials
-
Aug 13, 2026, 10:11Christina Kounoudi: Low-Dose vs. Therapeutic Anticoagulation in Extended VTE Prophylaxis
-
Aug 13, 2026, 10:10Jean Connors: Can Prothrombin Levels Improve Antiphospholipid Syndrome Risk Assessment?
-
Aug 13, 2026, 09:44Edward Lee Carter: Why Clinically Relevant Nonmajor Bleeding Demands Anticoagulation Stewardship?
-
Aug 13, 2026, 09:40Neel Bhut: Can AI Help Us Make Gene Therapy More Efficient?
-
Aug 13, 2026, 08:23Sally Mandour: The Diagnostic Challenge of Hypocellular Bone Marrow Failure
-
Aug 13, 2026, 08:11Cristiana Coneru: How the Gut Microbiome Influences Venous Thrombosis